Literature DB >> 25197383

Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis.

Sang Kyum Kim1, Si Young Song2, Sunghoon Kim3, Nam Hoon Cho1, Ga Won Yim3, Sang Wun Kim3, Young Tae Kim3, Eun Ji Nam3.   

Abstract

Pancreatic adenocarcinoma up-regulated factor (PAUF) expression is elevated in both ovarian tumors and pancreatic adenocarcinoma. However, PAUF expression in ovarian tumors according to histologic subtype and grade has not been investigated. In this study, we examined various clinicopathologic features of 24 patients with mucinous cystadenoma (MCA), 36 with mucinous borderline tumors (MBTs), and 46 with mucinous adenocarcinomas (MACs) according to PAUF expression status assessed using immunohistochemistry. We found that MACs more frequently stained positive for PAUF than did MCAs and MBTs (P < 0.0001). Although there was no significant differences with respect to other clinicopathologic characteristics of MACs according to PAUF expression status, patients with PAUF-weakly positive and PAUF-strongly positive MACs tended to have a shorter overall survival (OS) than those with PAUF-negative MAC, determined using a Kaplan-Meier analysis (P = 0.1885). After adjusting for various clinicopathologic parameters, PAUF positivity of MACs was a significant predictive factor for disease-free survival (DFS) (negative vs. weakly positive: P = 0.045, hazard ratio [HR] = 57.406, 95% confidence interval [CI]: 1.090-3022.596; and negative vs. strongly positive: P = 0.034, HR = 97.890, 95% CI: 1.412-6785.925). In conclusion, PAUF was more frequently expressed in MAC than in its benign and borderline counterparts, and was associated with a poor OS and DFS in MAC patients. Therefore, we suggest that PAUF may be a practical biomarker for histopathological categorization and a prognostic marker for patients with an ovarian mucinous tumor.

Entities:  

Keywords:  Mucinous tumor; PAUF; ovary; prognostic factor

Mesh:

Substances:

Year:  2014        PMID: 25197383      PMCID: PMC4152073     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  16 in total

1.  Mucinous carcinoma of the ovary. Clinicopathologic analysis.

Authors:  F Kikkawa; M Kawai; K Tamakoshi; N Suganuma; N Nakashima; Y Furuhashi; K Kuzuya; S Hattori; Y Arii; Y Tomoda
Journal:  Oncology       Date:  1996 Jul-Aug       Impact factor: 2.935

2.  Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis.

Authors:  J L Rutgers; R E Scully
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

3.  Natural history and outcome of mucinous carcinoma of the ovary.

Authors:  Maria B Schiavone; Thomas J Herzog; Sharyn N Lewin; Israel Deutsch; Xuming Sun; William M Burke; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2011-06-21       Impact factor: 8.661

4.  Mucinous tumor of low malignant potential ("borderline" or "atypical proliferative" tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion.

Authors:  Surapan Khunamornpong; Jongkolnee Settakorn; Kornkanok Sukpan; Prapaporn Suprasert; Sumalee Siriaunkgul
Journal:  Int J Gynecol Pathol       Date:  2011-05       Impact factor: 2.762

5.  Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.

Authors:  K R Lee; R E Scully
Journal:  Am J Surg Pathol       Date:  2000-11       Impact factor: 6.394

6.  Proliferating ovarian "epithelial" tumours: a clinico-pathological analysis of 144 cases.

Authors:  P Russell; H Merkur
Journal:  Aust N Z J Obstet Gynaecol       Date:  1979-02       Impact factor: 2.100

7.  Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up.

Authors:  H D Hoerl; W R Hart
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

8.  A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities.

Authors:  J Kaern; C G Tropé; V M Abeler
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type.

Authors:  S Siriaunkgul; K M Robbins; L McGowan; S G Silverberg
Journal:  Int J Gynecol Pathol       Date:  1995-07       Impact factor: 2.762

10.  Long-term follow-up of women with borderline ovarian tumors.

Authors:  S Kehoe; J Powell
Journal:  Int J Gynaecol Obstet       Date:  1996-05       Impact factor: 3.561

View more
  5 in total

1.  Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients.

Authors:  Chel Hun Choi; Joon-Yong Chung; Ho-Seop Park; Minsik Jun; Yoo-Young Lee; Byung-Gie Kim; Stephen M Hewitt
Journal:  Hum Pathol       Date:  2015-03-11       Impact factor: 3.466

2.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

Review 3.  Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.

Authors:  Robert Słotwiński; Sylwia Małgorzata Słotwińska
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

4.  Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer.

Authors:  Chel Hun Choi; Tae Heung Kang; Joon Seon Song; Young Seob Kim; Eun Joo Chung; Kris Ylaya; Seokho Kim; Sang Seok Koh; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

5.  PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer.

Authors:  Yeon Jeong Kim; Fen Jiang; Jin Park; Hyeon Hee Jeong; Ji Eun Baek; Seung-Mo Hong; Seong-Yun Jeong; Sang Seok Koh
Journal:  Front Pharmacol       Date:  2022-05-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.